Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

NCT02304809 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02304809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02304809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2014
Completion date
October 13, 2027
Enrollment
216 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic cancers, metastatic cancers, solid tumors